Non-invasive Prenatal Testing
High incidence rate of Down’s syndrome are the prominent trends that affect market growth.
WILMINGTON, DELAWARE , UNITED STATES, October 18, 2023 /EINPresswire.com/ — The Global “𝐍𝐨𝐧-𝐈𝐧𝐯𝐚𝐬𝐢𝐯𝐞 𝐏𝐫𝐞𝐧𝐚𝐭𝐚𝐥 𝐓𝐞𝐬𝐭𝐢𝐧𝐠 𝐌𝐚𝐫𝐤𝐞𝐭” was valued at US$ 2.1 Billion in 2022. It is projected to advance at a CAGR of 14.8% from 2022 to 2031 to reach more than US$ 8.4 Billion by the end of 2031.
𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐚 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐑𝐞𝐩𝐨𝐫𝐭 @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=374
Demand for non-invasive prenatal testing (NIPT) is increasing in several countries owing to the rise in number of doctors preferring advanced non-invasive DNA test for high-risk pregnancies, desire to delay pregnancy, and growth in pregnancy-related issues in the second or third trimester. The global market (NIPT) market is highly saturated, with the presence of a large number of players.
𝐍𝐨𝐧-𝐢𝐧𝐯𝐚𝐬𝐢𝐯𝐞 𝐏𝐫𝐞𝐧𝐚𝐭𝐚𝐥 𝐓𝐞𝐬𝐭𝐢𝐧𝐠 𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐧𝐭𝐫𝐨𝐝𝐮𝐜𝐭𝐢𝐨𝐧
Non-invasive prenatal testing (NIPT) is a novel genetic screening method based on the analysis of cell-free fetal DNA in the maternal plasma. NIPT screens for trisomy 21 (Down syndrome) as well as two other less common chromosome abnormalities: trisomy 13 and trisomy 18. Several companies are striving to create advanced screening methods that are sensitive and accurate in the early diagnosis of genetic abnormalities in infants.
Next-generation sequencing (NGS) is a commonly used technology for the identification of trisomy, micro-deletions, and aneuploidies in chromosomes. NGS-based noninvasive prenatal tests are different from other techniques, as they can be performed as early as 10 weeks of pregnancy. Additionally, other noninvasive prenatal tests offer about 96% accuracy, while NGS-based tests are more than 99% accurate.
𝐄𝐧𝐪𝐮𝐢𝐫𝐞 𝐁𝐞𝐟𝐨𝐫𝐞 𝐁𝐮𝐲𝐢𝐧𝐠 𝐭𝐡𝐞 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐫𝐞𝐩𝐨𝐫𝐭 𝐟𝐨𝐫 𝐯𝐢𝐭𝐚𝐥 𝐮𝐧𝐝𝐞𝐫𝐬𝐭𝐚𝐧𝐝𝐢𝐧𝐠𝐬- https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=374
𝐍𝐞𝐱𝐭-𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐨𝐧 𝐬𝐞𝐪𝐮𝐞𝐧𝐜𝐢𝐧𝐠 (𝐍𝐆𝐒) 𝐬𝐲𝐬𝐭𝐞𝐦𝐬 𝐥𝐞𝐚𝐝 𝐭𝐡𝐞 𝐠𝐥𝐨𝐛𝐚𝐥 𝐍𝐨𝐧-𝐢𝐧𝐯𝐚𝐬𝐢𝐯𝐞 𝐏𝐫𝐞𝐧𝐚𝐭𝐚𝐥 𝐓𝐞𝐬𝐭𝐢𝐧𝐠 (𝐍𝐈𝐏𝐓) 𝐦𝐚𝐫𝐤𝐞𝐭-
NGS systems provide precise and accurate detection of fetal chromosomal abnormalities by sequencing large amounts of DNA.
They are scalable to meet the increasing demand for NIPT, and their cost-effectiveness makes them preferable to other methods. NGS systems are widely available, improving access for pregnant women. Furthermore, NGS technology enables the development of new NIPT tests that detect a broader range of abnormalities, driving market growth.
In comparison to other techniques like NGS systems, ELISA kits are a generally accessible and affordable choice for NIPT. They are useful for point-of-care testing and smaller laboratories since they are comparatively simple. Trisomy 21 and trisomy 18 are two frequent fetal chromosomal disorders that ELISA tests are highly accurate at identifying. A greater spectrum of abnormalities is detected by ELISA-based NIPT tests, fostering continued market expansion.
𝐇𝐨𝐰 𝐚𝐫𝐞 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐑𝐞𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐢𝐳𝐢𝐧𝐠 𝐭𝐡𝐞 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲?
The Non-invasive Prenatal Testing industry is highly competitive, with several players operating globally. The market is characterized by the presence of both established as well as emerging players. The key players in the market are engaged in strategic partnerships, collaborations, and mergers and acquisitions to expand their market presence.
• Berry Genetics
• BGI
• Laboratory Corporation of America Holdings
• Agilent Technologies, Inc.
• Illumina, Inc.
• F. Hoffmann-La Roche Ltd.
• Natera, Inc.
• PerkinElmer Inc.
• Eurofins LifeCodexx AG
• IGENOMIX
• Pacific Biosciences
𝐇𝐚𝐯𝐞 𝐀𝐧𝐲 𝐐𝐮𝐞𝐫𝐲? 𝐀𝐬𝐤 𝐎𝐮𝐫 𝐄𝐱𝐩𝐞𝐫𝐭𝐬: https://www.transparencymarketresearch.com/sample/sample.php?flag=ASK&rep_id=374
𝐊𝐞𝐲 𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐬 𝐨𝐟 𝐭𝐡𝐞 𝐍𝐨𝐧-𝐢𝐧𝐯𝐚𝐬𝐢𝐯𝐞 𝐏𝐫𝐞𝐧𝐚𝐭𝐚𝐥 𝐓𝐞𝐬𝐭𝐢𝐧𝐠 𝐌𝐚𝐫𝐤𝐞𝐭
𝐓𝐞𝐬𝐭 𝐓𝐲𝐩𝐞
• Materni21
• Harmony
• Panorama
• Verifi
• NIFTY
• Others
𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧
• Trisomy
• Micro-deletions Symptoms
• Others (including sex chromosomes disorders)
𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲
• NGS
• WGS
• Others
𝐄𝐧𝐝-𝐮𝐬𝐞𝐫
• Hospitals
• Diagnostic Laboratories
• Others
𝐊𝐞𝐲 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭𝐬 𝐢𝐧 𝐆𝐥𝐨𝐛𝐚𝐥 𝐍𝐨𝐧-𝐢𝐧𝐯𝐚𝐬𝐢𝐯𝐞 𝐏𝐫𝐞𝐧𝐚𝐭𝐚𝐥 𝐓𝐞𝐬𝐭𝐢𝐧𝐠 𝐌𝐚𝐫𝐤𝐞𝐭
• 𝐈𝐧 𝐉𝐚𝐧𝐮𝐚𝐫𝐲 𝟐𝟎𝟐𝟐, QIAGEN collaborated with Atila BioSystems to supply non-invasive prenatal testing (NIPT) solutions to QIAGEN’s dPCR business
• 𝐈𝐧 𝐉𝐮𝐥𝐲 𝟐𝟎𝟐𝟏, Pacific Biosciences signed a definitive merger agreement to acquire Omniome, a San Diego-based company developing a highly differentiated, proprietary short-read sequencing platform capable of delivering high accuracy. The company chose Omniome due to its novel approach to getting a precise short-read sequencing platform to fast-growing clinical application areas in oncology, transcriptomics, metagenomics, and non-invasive prenatal testing (NIPT).
• 𝐈𝐧 𝟐𝟎𝟏𝟕, 𝐍𝐚𝐭𝐞𝐫𝐚, 𝐈𝐧𝐜. launched Vistara, a NIPT solution that screens single gene abnormalities across 30 genes. It is an alternative/complement to Panorama and screens for severe skeletal, cardiac, and oncological conditions that are related to cognitive disorders and require surgical interventions.
𝐁𝐫𝐨𝐰𝐬𝐞 𝐌𝐨𝐫𝐞 𝐑𝐞𝐥𝐚𝐭𝐞𝐝 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐛𝐲 𝐓𝐫𝐚𝐧𝐬𝐩𝐚𝐫𝐞𝐧𝐜𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡-
Neurostimulation Devices Market to Experience Robust 12.0% CAGR
Healthcare ERP Market to Flourish at 6.5% CAGR, Surpassing US$ 9.6 Bn
Nikhil Sawlani
Transparency Market Research Inc.
+ +1 518-618-1030
[email protected]
Visit us on social media:
Twitter
LinkedIn
YouTube
